Brief: Immuneering Doses First Patient In Early-to-Mid Stage Study Of Drug for Solid Tumors

Immuneering

28/11/2022 11:55

Nov 28 (Reuters) - Immuneering Corp  IMRX.O :
    * IMMUNEERING ANNOUNCES FIRST PATIENT DOSED IN ITS PHASE
1/2A
CLINICAL TRIAL OF IMM-1-104 IN ADVANCED SOLID TUMORS WITH RAS
MUTATIONS
    * IMMUNEERING CORP - IMM-1-104 BEING TESTED IN FIRST
ALL-COMERS
RAS CLINICAL TRIAL BELIEVED TO BE CONDUCTED TO DATE
    * IMMUNEERING CORP - PHASE 1 PORTION OF STUDY MAY ENROLL UP
TO
APPROXIMATELY 42 PATIENTS AT FIVE CLINICAL SITES IN UNITED
STATES

Source text for Eikon:  ID:nGNX37mMJ7 
Further company coverage:  IMRX.O 
 ((Reuters.Briefs@thomsonreuters.com;))